Does the route of administration matter in preventing CNS relapse in agressive B-cell lymphomas? Marina Konopleva, MD, PhD, discusses venetoclax resistance in AML during SOHO 2022 Jia Ruan, spoke on emerging treatment options for MCL in this interview from SOHO 2022. A retrospective study observed a three-year OS rate of 66.7% in primary MF patients and 55.6% in secondary MF patients... Gilteritinib plus induction and consolidation chemotherapy demonstrated acceptable safety outcomes. Dr. Konopleva spoke to Blood Cancers Today during the 2022 SOHO Annual Meeting. Dr. Coombs discussed these challenges during the 10th Annual Meeting of the Society of Hematologic Oncology. Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ... Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice... Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future. Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL). Jia Ruan, MD, PhD, discusses emerging treatment options for mantle cell lymphoma at the 2022 SOHO Annual Meeting. The phase III BRUIN MCL-321 is currently enrolling patients to compare the efficacy of pirtobrutinib versus other BTKi. Updated results from a phase I/IIb study demonstrated promising efficacy for the novel agent pirtobrutinib. Catherine Coombs, MD, discusses Bruton’s tyrosine kinase inhibitors at the 2022 SOHO Annual Meeting. Alexey V. Danilov, MD, PhD, spoke with Blood Cancers Today about his 2022 SOHO Annual Meeting presentation. The use of extracorporeal photopheresis declined in patients with Sézary syndrome as the COVID-19 pandemic began. The efficacy of enasidenib in patients with AML depends on the mutation type. A conditioning regimen of clofarabine plus total body irradiation led to a two-year overall survival rate of 43% Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...